TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Blood tests that measure Alzheimer’s-related proteins can help clinicians assess people with cognitive symptoms, potentially reducing reliance on spinal taps and PET scans. The supplied report says four tests had received FDA clearance by August 2026, but the tests are not stand-alone diagnoses and their role, access and insurance coverage remain important limits.
Blood-based biomarkers are measurable molecules that can indicate disease-related changes. In Alzheimer’s, beta-amyloid can accumulate in plaques between nerve cells, while tau can form tangles inside cells. Small fragments of these proteins reach the bloodstream, where laboratory tests can measure them.
Tests may assess the Aβ42/40 ratio, comparing two forms of beta-amyloid, or phosphorylated tau, including pTau-181 and pTau-217. A lower Aβ42 relative to Aβ40 can indicate amyloid plaque buildup. Elevated pTau-217 is associated with Alzheimer’s-related amyloid and tau changes, although the test is not simply a direct measure of tau tangles in the brain.
These tests are intended to support evaluation of people who already have cognitive symptoms, rather than serve as general screening for everyone. Clinicians interpret results alongside a person’s symptoms and other clinical information; further testing, such as a spinal tap or amyloid PET scan, may still be needed.
Blood Tests May Shorten Diagnostic Delays
A blood draw is less invasive than a lumbar puncture and may be easier to access than a specialized PET scan. The tests could help clinicians decide earlier which patients need additional evaluation, a matter that may affect treatment discussions for people at an early stage of Alzheimer’s.
Being Patient cites a 2024 study of 1,213 patients in Sweden, published in JAMA, in which primary care doctors correctly identified Alzheimer’s 63% of the time and dementia specialists 73% of the time; a blood test was about 90% accurate in both settings. Those figures describe that study and should not be treated as a guarantee of performance for every test or patient.
A separate modeling study projected that a blood test confirming amyloid could reduce a roughly 36-month diagnostic timeline for people over 65 with memory problems to about six months. That was a projection, not a reported outcome from a clinical rollout. The potential time savings matter because Leqembi and Kisunla are approved for people in early disease stages, but the supplied material does not establish that blood testing alone speeds treatment or improves outcomes.
Products Worth Considering
Greenworks 40V String Trimmer and Blower Combo with 2.0 Ah Battery
Husqvarna Automower 550 Commercial Robotic Lawn Mower
Greenworks 40V Cordless Leaf Blower/Vacuum, 505 CFM, 5.0 Ah Battery and Charger
As an affiliate, we earn on qualifying purchases.
From Spinal Taps to Blood Biomarkers
For decades, the report says, the main ways to confirm Alzheimer’s-related brain changes during life were a spinal tap, which samples fluid around the brain and spinal cord, and an amyloid PET scan. Both can involve cost, access barriers and delays. Blood tests offer a less invasive route to measuring protein signals associated with those changes.
The report says the FDA had cleared four tests by August 2026 for helping evaluate people with cognitive symptoms. It also notes that other tests are sold through laboratories without FDA review. FDA clearance and availability should not be confused with a claim that every blood test has the same validation or intended use.
Maria C. Carrillo, the Alzheimer’s Association’s chief science officer, described the clearances as adding validated options for clinicians. Howard Fillit of the Alzheimer’s Drug Discovery Foundation told Being Patient that pTau-217 appeared to be emerging as the best blood test. These are attributed expert assessments, not evidence that one test is appropriate for every patient.
“Each FDA clearance gives clinicians another validated option to work with.”
— Maria C. Carrillo, chief science officer at the Alzheimer’s Association, in a statement in August 2026
Limits, Coverage and Test Differences
A positive or negative result is not, by itself, a diagnosis. The report says clinicians may use blood-test results to help confirm or rule out Alzheimer’s as a cause of symptoms, but it does not provide the names, performance specifications or intended-use details for all four cleared tests in the supplied material. Results and accuracy may vary by test and clinical setting.
It is also unclear how consistently blood tests will be covered by insurance; the report says coverage remains variable. The impact of testing on real-world diagnosis times and access to treatment is not established by the cited simulation, which projected possible effects rather than measuring them after implementation. The supplied source does not establish that these tests are suitable for people without cognitive symptoms.
Clinical Use and Access Remain Key
Clinicians will need to select tests suited to the patient and interpret results within a broader assessment, including whether additional confirmation is appropriate. Patients considering testing should discuss its purpose, limitations, costs and coverage with a qualified health professional; this article is not medical advice.
Further evidence on performance across different patient groups, practical diagnostic timelines and insurance access will help clarify how widely the tests can be used. The source report’s count is stated through August 2026, so later regulatory decisions or changes in coverage are not reflected here.
Key Questions
What do Alzheimer’s blood tests measure?
They measure blood levels or ratios of proteins associated with Alzheimer’s-related brain changes, including beta-amyloid and phosphorylated tau such as pTau-217.
Can a blood test diagnose Alzheimer’s on its own?
No. The tests are intended to help clinicians evaluate people with cognitive symptoms. Results need to be considered with symptoms and other clinical information, and additional tests may be needed.
Who are the tests intended for?
The report describes FDA-cleared tests for people showing signs or symptoms of cognitive impairment. It does not present them as general screening tests for everyone.
How do blood tests compare with a PET scan or spinal tap?
A blood draw is less invasive and may be easier to access. PET scans and spinal taps remain diagnostic options, and clinicians may still use them when further evaluation is needed.
Are the tests covered by insurance?
Coverage is variable, according to the report. Patients should check with their insurer and clinician about the cost and coverage of a specific test.
Source: beingpatient.com
